Oxular in Retina Today

Oxular was mentioned in this great article by Dr. Sivaprasad in Retina Today, on the promise of reduced treatment burden for DME patients via sustained-release steroids. Oxular is a key innovator in long-lasting retinal treatments and precise suprachoroidal space delivery, and some of the advantages behind our approach are highlighted here. Simply put, we believe it’s going to lead to better outcomes for patients, physicians and healthcare systems. Our lead program combines our Oxulumis®️ microcatheter and a sustained-release formulation of dexamethasone to target 12 months treatment durability for DME. We’re preparing clinical trials now.
Scroll to Top